CAR T-cell therapy: Reprogramming the immune system to treat cancer | Rob Weinkove | TEDxTauranga

Summary

Rob Weinkove describes how cancer immunotherapy aims to make the immune system a more targeted tool against cancer. He contrasts this goal with bone-marrow transplants, which can replace a patient’s blood and immune system but may cause severe, unpredictable complications.

Two patients he treated illustrate the contrast: donor immune cells helped one patient’s lymphoma remain in remission for more than a decade, while another patient died after the transplanted immune cells attacked her body.

Immune-system functions

• Lymph nodes are meeting places where immune cells exchange information.
• B cells and T cells help coordinate adaptive immune responses. B cells can multiply rapidly and alter the genes encoding their antibody receptors, allowing selection of cells that recognize an infection more effectively. Weinkove calls this process affinity maturation.
• T cells help monitor the body for abnormal cells and can destroy some that show signs of cancer-related mutations. Cancer can develop when cells acquire changes that let them evade this immune surveillance.
• Existing cancer immunotherapies include artificial antibodies, treatments that boost T-cell activity, and bone-marrow transplants. Each can be useful, but none works for every cancer or patient, and all can have side effects.

CAR T-cell therapy

CAR T-cell therapy reprograms a patient’s T cells to recognize and attack cancer cells. The method described is:

1. Collect blood from the patient and separate out the T cells.
2. Add a gene that makes the cells produce a chimeric antigen receptor (CAR). This receptor gives T cells a new way to recognize a target on cancer cells, drawing on antibody-recognition features.
3. Grow the modified cells in the laboratory, typically expanding their numbers about a hundredfold over seven to ten days.
4. Freeze and safety-test the cells.
5. Give the patient a low dose of chemotherapy as conditioning, then infuse the CAR T cells into a vein.
6. Monitor the patient closely as the cells find and attack cancer cells, multiply, and may cause inflammatory reactions. Treatment may be needed to control an excessive immune response.
7. After the main response, most CAR T cells decline in number, though some may persist and provide longer-term protection.

Weinkove reports that, in clinical trials involving some patients with blood cancers, more than four in five went into remission. Responses were also seen in some people whose disease had resisted other chemotherapy or returned after a bone-marrow transplant. These results are trial findings, not a guarantee of success for every patient.

At the Malaghan Institute in Wellington, the team was preparing to make the treatment available locally. Manufacturing requires a strictly controlled, clean environment because the cells will be returned to patients whose immune systems are compromised. The talk also describes the possible future development of CAR T cells from healthy donors, which would require additional modifications to make them safe. Wider use would depend on clinical expertise, suitable regulation, fair access, logistics, and funding.

Researchers and sources featured

• Rob Weinkove — Hematologist and speaker, leading the CAR T-cell research programme at the Malaghan Institute.
• Malaghan Institute — Research institute developing and manufacturing the CAR T-cell therapies described in the talk.
• Brigitta and Evelyn — Staff shown working in the institute’s cell-therapy facility.
• No external publications or other research sources are named in the subtitles.